^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    anti-MUC1 CAR-T cells

    i
    Other names: anti-MUC1 CAR-T cells
    Associations

    News

    Trials
    Company:
    Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology
    Drug class:
    MUC1-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over3years
    [VIRTUAL] Clinical study of PD-1 disrupted anti-MUC1 CAR-T cells in patients with advanced oesophageal cancer (ESMO-GI 2021)
    The efficacy of this unique combined therapy is currently being assessed. Our limited data indicate that the best achievable clinical outcome is SD meaning that the anticancer effect of current CART cells with PD-1 inhibition on solid tumours have a ceiling.
    Clinical • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • IL6 (Interleukin 6)
    |
    anti-MUC1 CAR-T cells